Summary: Catalent Biologics presents a case study on the investigational COVID-19 therapeutic candidate, lenzilumab, and its development from gene to late stage clinical trials.
Summary: Enzymes can be challenging to express and scale up to become biologic therapies. In order to develop their optimized tissue plasmigen activator (tPA) to treat patients with hemorrhagic stroke…
Summary: Which 11 biotech startups stand out from the pack that have launched in 2020? Watch the Endpoints 11 – Startups to Watch Awards, a virtual event celebrating innovative science and entrepreneurship.
Summary: Hear Catalent Biologics Region President, address challenges in manufacturing scale-up and discuss how partnerships are enabling pharma companies of all sizes to meet unprecedented timelines as they race toward delivering vaccines to patients worldwide.
Summary: Download this webinar to learn how our RED-106 noncleavable maytansine linker-payload is well-tolerated, offering wider therapeutic windows compared to other technologies.
Summary: Learn why speed and efficiency are top priorities for companies looking to develop a clonal cell line for drug substance manufacturing.
